Related Experiment Video

Updated: Dec 26, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.6K

Fisetin Modulates Human Oral Squamous Cell Carcinoma Proliferation by Blocking PAK4 Signaling Pathways

Yanshu Li1,2,3, Shiheng Jia3,4, Wei Dai5,6

  • 1Key Laboratory of Cell Biology, Ministry of Public Health, China Medical University, Shenyang, Liaoning, People's Republic of China.

Drug Design, Development and Therapy
|March 12, 2020
PubMed
Abstract

Insights

Fisetin, a natural flavonoid, inhibits oral squamous cell carcinoma (OSCC) growth by targeting PAK4 signaling pathways. This study reveals fisetin

Area of Science:

  • Oncology
  • Molecular Biology
  • Natural Products Chemistry

Background:

  • Oral squamous cell carcinoma (OSCC) poses a significant global health burden.
  • Identifying novel therapeutic targets and bioactive compounds for OSCC is crucial.
  • Fisetin, a flavonoid, exhibits anti-proliferative effects in OSCC, but its mechanism remains unclear.

Purpose of the Study:

  • To elucidate the molecular mechanism of fisetin's anti-cancer effects in OSCC.
  • To investigate fisetin's impact on OSCC cell proliferation, apoptosis, and migration.
  • To evaluate fisetin's therapeutic potential against OSCC in vitro and in vivo.

Main Methods:

  • In vitro assays: Colony formation, cell viability, Boyden chamber, and wound healing.
  • In vivo studies: Tumor xenograft assay in mice.
  • Molecular analysis: Western blot to assess protein expression (PAK4).

Main Results:

  • Fisetin significantly suppressed OSCC cell proliferation and induced apoptosis.
  • Fisetin repressed PAK4 expression, a key mediator of OSCC progression.
  • Fisetin attenuated OSCC cell migration by inhibiting PAK4 signaling pathways and demonstrated anti-tumor growth in vivo.

Conclusions:

  • Fisetin demonstrates potent anti-cancer properties against OSCC.
  • Targeting PAK4 signaling pathways with fisetin offers a promising therapeutic strategy.
  • Fisetin holds potential for the development of novel OSCC treatments.
Keywords:
OSCCPAK4PARPfisetin

More Related Videos

Analysis of Cancer Cell Invasion and Anti-metastatic Drug Screening Using Hydrogel Micro-chamber Array HMCA-based Plates08:32

Analysis of Cancer Cell Invasion and Anti-metastatic Drug Screening Using Hydrogel Micro-chamber Array HMCA-based Plates

Published on: October 25, 2018

9.4K
A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery07:20

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery

Published on: February 28, 2020

10.3K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
11.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K